Loading organizations...
Riptide Ventures operates as a network-powered angel syndicate, specializing in sourcing, diligencing, and supporting early-stage companies. It provides a streamlined path for founders to secure angel investment, combining individual member decisions with the collective expertise and networks of its diverse members, primarily for ventures in regulated industries.
Managing Partner Michael Leffer established the firm in 2022. His experience, including incubating Riptide at Early Light Ventures and his role at Squadra Ventures, alongside entrepreneurial and military service, informed the insight to efficiently connect seasoned angel investors with promising startups through swift, collective early-stage capital deployment.
Riptide Ventures targets founders addressing genuine market needs with demonstrable customer demand, especially within regulated sectors. Its vision centers on fostering an environment where angel investors actively deploy their expertise and connections, empowering portfolio companies to achieve substantial growth and realize their full potential.
Riptide Ventures has 3 tracked investments across 3 companies. The latest tracked deal is $6.5M Series A in Poppy Flowers in December 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 6, 2023 | Poppy Flowers | $6.5M Series A | Michigan Capital Network | Angeles Investors, Front Porch Ventures, IDEA Fund Partners, Techstars |
| Oct 12, 2022 | Vita Therapeutics | $31.0M Series B | James Peyer, Dennis J. "chip" Wilson | Cedars Sinai Medical Center, TEDCO |
| Jul 1, 2017 | Previse | $3.0M Seed | Hambro Perks | 75 & Sunny, FJ Labs, Moonshots Capital, Next47, Redbud VC, Summit Partners, Clark Landry, Gaingels, TEDCO, Thomas Osha, Founders Factory |
